The numbers: Third-quarter profit more than doubled to $74 million, or $1.25 a share. Revenue advanced 7% to $326 million. The company's operating margin widened from 15% to 17%. Edwards has a liquid balance sheet, with $290 million of cash and $102 million of debt. The stock: Edwards Lifesciences increased 58% in the past 12 months, more than major U.S. indices. The stock trades at a price-to-earnings ratio of 24, a discount to health-care-equipment peers. Edwards doesn't pay dividends.